Relief Therapeutics Holding SA
SIX:RLF
Gross Margin
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Peer Comparison
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| CH |
|
Relief Therapeutics Holding SA
SIX:RLF
|
437m CHF |
Loading...
|
|
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
Loading...
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
399.2B USD |
Loading...
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
202.4B USD |
Loading...
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
188.1B USD |
Loading...
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
121B USD |
Loading...
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
Loading...
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
82.1B USD |
Loading...
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
74.2B AUD |
Loading...
|
|
| NL |
|
argenx SE
XBRU:ARGX
|
44.2B EUR |
Loading...
|
|
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR |
Loading...
|
Market Distribution
| Min | -13 700% |
| 30th Percentile | 34.9% |
| Median | 49.4% |
| 70th Percentile | 65.3% |
| Max | 137.7% |
Other Profitability Ratios
Relief Therapeutics Holding SA
Glance View
RELIEF THERAPEUTICS Holding AG is a clinical stage biotechnology company. The company is headquartered in Geneve, Geneve and currently employs 55 full-time employees. The company went IPO on 2011-09-19. The Company’s objective is to provide patients with therapeutic relief in serious diseases with high unmet medical need, as well as to focus on developing treatments for respiratory diseases. The company specializes in clinical-stage projects based on molecules of natural origin (peptides and proteins with a history of clinical use and either initial human activity with efficacy data or a strong scientific rationale. Its lead compound is RLF-100 (aviptadil), a synthetic human vasoactive intestinal peptide (VIP) with a multifaceted mode of action in respiratory indications. RLF-100 is being investigated in two placebo-controlled U.S. phase 2b/3 clinical trials in respiratory deficiency due to COVID-19. Its RLF-100 is also used for pulmonary sarcoidosis. The firm is also involved in the clinical development of RLF-100 that is in planning stage for other indications in acute and chronic lung diseases.
See Also
Gross Margin is calculated by dividing the Gross Profit by the Revenue.
The current Gross Margin for Relief Therapeutics Holding SA is 60.2%, which is below its 3-year median of 69.7%.
Over the last 3 years, Relief Therapeutics Holding SA’s Gross Margin has decreased from 78.4% to 60.2%. During this period, it reached a low of 60.2% on Jun 30, 2025 and a high of 79.4% on Dec 31, 2022.
